BAYN.DE : Summary for BAYER AG NA O.N. - Yahoo Finance

U.S. Markets close in 1 hr 53 mins

Bayer Aktiengesellschaft (BAYN.DE)


XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
108.70+3.50 (+3.33%)
At close: 5:35PM CEST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close105.20
Open107.25
Bid0.00 x 28400
Ask0.00 x 2100
Day's Range106.95 - 108.70
52 Week Range83.45 - 112.00
Volume3,259,817
Avg. Volume1,758,993
Market Cap89.93B
BetaN/A
PE Ratio (TTM)19.98
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • J&J, Bayer Accused of Hiding Blockbuster Blood Thinner's Dangers
    Bloomberg1 hour ago

    J&J, Bayer Accused of Hiding Blockbuster Blood Thinner's Dangers

    Joseph Boudreaux says taking Johnson & Johnson’s blood-thinning drug Xarelto was one of the biggest mistakes of his life.

  • Reuters20 hours ago

    EU drugmakers urge June decision on new location for watchdog

    Europe's drugmakers pushed for a decision as early as June on the new location for the headquarters of the bloc's medicines watchdog, which will relocate from London after Britain's decision to leave the EU. The new location will be decided by the EU's heads of state, whose next meeting as the European Council is scheduled for June 22-23. "The Council's deliberations on the Agency's future location need to be conducted on the basis of very essential criteria and put for decision as early on as possible, preferably at its meeting in June this year," European pharma lobby group EFPIA said in a statement on Monday signed by 19 top executives at member companies including Pfizer, Novartis, Sanofi and Roche.

  • Reuters7 days ago

    OncoMed's lung cancer drug fails mid-stage study, shares tumble

    OncoMed Pharmaceuticals Inc's shares were jolted for a second time in a week after the company said on Monday its experimental lung cancer drug failed a mid-stage study. Including those losses, OncoMed's market valuation has halved since the company said last week it would discontinue a trial testing another cancer drug. "Based on the events of today and last week, we will be undertaking a comprehensive portfolio prioritization review immediately," said Chief Executive Paul Hastings.